Voyager Therapeutics (VYGR) Revenue & Revenue Breakdown
Voyager Therapeutics Revenue Highlights
Latest Revenue (Y)
$250.01M
Latest Revenue (Q)
$29.58M
Voyager Therapeutics Revenue by Period
Voyager Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $250.01M | 511.16% |
| 2022-12-31 | $40.91M | 9.33% |
| 2021-12-31 | $37.41M | -78.14% |
| 2020-12-31 | $171.13M | 63.93% |
| 2019-12-31 | $104.39M | 1270.14% |
| 2018-12-31 | $7.62M | -24.82% |
| 2017-12-31 | $10.13M | -28.73% |
| 2016-12-31 | $14.22M | -17.96% |
| 2015-12-31 | $17.33M | 100.00% |
| 2014-12-31 | - | - |
Voyager Therapeutics generated $250.01M in revenue during NA 2023, up 511.16% compared to the previous quarter, and up 3281.38% compared to the same period a year ago.
Voyager Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $29.58M | 51.56% |
| 2024-03-31 | $19.52M | -78.33% |
| 2023-12-31 | $90.06M | 1851.91% |
| 2023-09-30 | $4.61M | -4.92% |
| 2023-06-30 | $4.85M | -96.77% |
| 2023-03-31 | $150.48M | -466.25% |
| 2022-12-31 | $-41.09M | -200.00% |
| 2022-09-30 | $41.09M | 5670.51% |
| 2022-06-30 | $712.00K | 8.21% |
| 2022-03-31 | $658.00K | -97.66% |
| 2021-12-31 | $28.07M | 1794.26% |
| 2021-09-30 | $1.48M | 9.21% |
| 2021-06-30 | $1.36M | -79.13% |
| 2021-03-31 | $6.50M | -0.55% |
| 2020-12-31 | $6.54M | -94.45% |
| 2020-09-30 | $117.84M | 310.87% |
| 2020-06-30 | $28.68M | 58.75% |
| 2020-03-31 | $18.07M | -44.71% |
| 2019-12-31 | $32.67M | 59.91% |
| 2019-09-30 | $20.43M | -55.66% |
| 2019-06-30 | $46.09M | 786.80% |
| 2019-03-31 | $5.20M | 158.81% |
| 2018-12-31 | $2.01M | -4.11% |
| 2018-09-30 | $2.09M | -18.68% |
| 2018-06-30 | $2.58M | 173.35% |
| 2018-03-31 | $942.00K | -85.15% |
| 2017-12-31 | $6.34M | 452.70% |
| 2017-09-30 | $1.15M | -2.46% |
| 2017-06-30 | $1.18M | -19.60% |
| 2017-03-31 | $1.46M | -38.02% |
| 2016-12-31 | $2.36M | -28.60% |
| 2016-09-30 | $3.31M | -11.08% |
| 2016-06-30 | $3.72M | -22.98% |
| 2016-03-31 | $4.83M | -2.17% |
| 2015-12-31 | $4.94M | - |
| 2015-09-30 | $4.94M | 1.09% |
| 2015-06-30 | $4.88M | 89.60% |
| 2015-03-31 | $2.58M | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Voyager Therapeutics generated $29.58M in revenue during Q2 2024, up 51.56% compared to the previous quarter, and up 19.66% compared to the same period a year ago.
Voyager Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VYGR | Voyager Therapeutics | $250.01M | $29.58M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| LPTX | Leap Therapeutics | - | - |
| ANNX | Annexon | - | - |
| TERN | Terns Pharmaceuticals | - | - |
VYGR Revenue FAQ
What is Voyager Therapeutics’s yearly revenue?
Voyager Therapeutics's yearly revenue for 2023 was $250.01M, representing an increase of 511.16% compared to 2022. The company's yearly revenue for 2022 was $40.91M, representing an increase of 9.33% compared to 2021. VYGR's yearly revenue for 2021 was $37.42M, representing a decrease of -78.14% compared to 2020.
What is Voyager Therapeutics’s quarterly revenue?
Voyager Therapeutics's quarterly revenue for Q2 2024 was $29.58M, a 51.56% increase from the previous quarter (Q1 2024), and a 509.48% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $19.52M, a -78.33% decrease from the previous quarter (Q4 2023), and a -87.03% decrease year-over-year (Q1 2023). VYGR's quarterly revenue for Q4 2023 was $90.06M, a 1851.91% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Voyager Therapeutics’s revenue growth rate?
Voyager Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 568.20%, and for the last 5 years (2019-2023) was 139.49%.